Research programme: influenza virus vaccine - HepaLife
Latest Information Update: 23 Dec 2010
At a glance
- Originator HepaLife Technologies
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Influenza virus infections
Most Recent Events
- 10 Jul 2006 Preclinical trials in Influenza virus infections in USA (Injection)